**In Vitro** Effect of Fenugreek Extracts on Intestinal Sodium-dependent Glucose Uptake and Hepatic Glycogen Phosphorylase A

M. AL-HABORI, A. RAMAN, M. J. LAWRENCE and P. SKETT

*Department of Clinical Biochemistry, University of Sana’a, Sana’a, Republic of Yemen; Department of Pharmacy, King’s College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 8WA, UK; Institute of Biomedical and Life Sciences, West Medical Building, University of Glasgow, Glasgow G12 8QQ, UK

(Received 9 March 2001; In final form 25 April 2001)

Fenugreek (*Trigonella foenum-graecum* L. seed) is a food with traditional medicinal use in diabetes. Beneficial effects have been demonstrated in diabetic animals and both insulin-dependent and non-insulin-dependent diabetic subjects. Effects of a lipid extract A, crude ethanolic extract B, further sub-fractions of B (saponin-free C, saponin D and sapogenin E) and a gum fibre fraction F on intestinal sodium-dependent glucose uptake were investigated *in vitro* using rabbit intestinal brush border membrane vesicles. All fractions except A inhibited glucose-uptake at 0.33 and/or 3.3 mg/mL (p < 0.001). Greatest inhibition was observed with fractions D and E. Diosgenin and trigonelline (compounds reported in fenugreek) also inhibited glucose-uptake (IC₅₀ values approximately 3 mg/mL, equivalent to 8 mM and 19 mM respectively) but did not account for the activity of the crude extracts. Fenugreek extracts had no effect on basal levels of glycogen phosphorylase a (HGPa) activity in rat hepatocyte suspensions. However, fractions C and E caused a marginal but statistically significant inhibition (18.9 and 15.1% respectively, p < 0.05) of glucagon induction of this enzyme suggesting a glucagon-antagonist effect. Diosgenin (1.65 mg/ml; 4 mM) inhibited glucagon-induced HGPa activity by 20% (p < 0.05), and was more effective than trigonelline (non significant inhibition of 9.4% at 1.65 mg/ml, 10 mM).

**Keywords:** Fenugreek; *Trigonella*; SGLT-1; BBMV; Glycogen phosphorylase a; Hepatocytes

**INTRODUCTION**

Diabetes mellitus affects 3–5% of people living in Western countries and is a heterogeneous disorder with varying prevalence among different ethnic groups. Based on the emerging relationship between hyperglycaemia and degree of glycaemic control on one side and the development of microvascular and macrovascular complications on the other, there is a growing interest in the inclusion of beneficial food substances in the diet to assist the control of glucose levels.

*Corresponding author. Tel.: +44-20-7848-4810, Fax: +44-20-7848-4800, e-mail: amala.raman@kcl.ac.uk*
Fenugreek (Trigonella foenum-graecum L.) is an annual plant from the family Papilionaceae-Leguminosae, and is extensively cultivated as a food crop in India, the Mediterranean region, North Africa and Yemen. Main uses of the seeds (often referred to as “fenugreek”) are as a spice and, when defatted, as a flour. Fenugreek has also been credited with many medicinal properties (reviewed by AL-Habori and Raman, 1998). In particular, anti-diabetic and hypocholesterolaemic effects have been demonstrated in diabetic animals and both insulin-dependent and non-insulin-dependent (Type I and Type II) diabetes mellitus. For example, consumption of 15g of ground fenugreek 15 minutes before a standardised meal, reduced the postprandial elevation of plasma glucose by an average of 20% (p < 0.05) in 17 out of 21 Type II patients. In a group of 11 Type I patients, consumption of 100 g of fenugreek daily for 10 days resulted in a lowering of fasting blood glucose from 15.1 to 10.9 mM, a 20% decrease in the area under the glucose tolerance curve and a 54% fall in 24-hour urinary sugar excretion.

The anti-diabetic activity of fenugreek is primarily associated with the defatted fraction of the seeds, and can be largely attributed to their saponin and high fibre content but not to the major alkaloid trigonelline. Suggested mechanisms for fenugreek’s anti-diabetic effects include delayed gastric emptying and interference with glucose absorption due to high fibre content, inhibition of pancreatic α-amylase and intestinal disaccharidase enzymes, or the presence of an orally active principle capable of inducing hypoglycaemia or enhanced plasma insulin levels. The compound 4-hydroxyisoleucine, which represents up to 80% of free amino acids in fenugreek seeds, was found to possess insulin-secretagogue properties both in pancreatic islets in vitro and in rats and dogs in vivo.

In the light of the reported beneficial role of fenugreek in the management of diabetes, and its complex chemical profile, the aim of this study was to investigate further the possible mechanisms and target sites through which fenugreek may act, by making use of in vitro models. We have prepared a range of fractions to investigate the role of different fenugreek constituents in its anti-diabetic activity. Most studies have employed the defatted seeds. However, we have also investigated the activity of the lipid fraction which would normally be discarded. The defatted ethanol extract (used in many studies) would be expected to contain saponins and other polar materials. We have used n-butanol to separate the saponins from water-soluble constituents of fenugreek. Since saponins are likely to undergo hydrolysis in the gastrointestinal tract an aglycone (sapogenin) extract was prepared. Finally we have also tested the effect of trigonelline and diosgenin (a sapogenin) two well known compounds derived from fenugreek.

The effects of the fenugreek fractions on intestinal glucose uptake was investigated using isolated intestinal brush border membrane vesicles (BBMVs) prepared from the apical membrane microvilli of rabbit intestinal enterocytes and effects on liver glycogen degradation examined using isolated rat hepatocyte suspensions. A polysaccharide gum fibre fraction was tested in the intestinal model alone since intact polysaccharides would not be expected to reach the liver.

There is evidence from rat models that the expression of the sodium-dependent glucose transporter (SGLT-1) and a sodium-independent transporter GLUT-2 is raised in the diabetic state, thus increasing the likelihood of hyperglycaemia following a meal. The major component of glucose transport in rat isolated enterocytes was found to be due to SGLT-1 which can be blocked by the plant-derived glycoside phloridzin (phlorizin). BBMV comprise spherical vesicles in which SGLT-1 is expressed in the membrane, the outer surface representing the intestinal lumen and the core of the vesicle the intestinal cell. The advantage of using BBMV

\[ \text{INTERNATIONAL JOURNAL OF EXPERIMENTAL DIABETES RESEARCH} \]
in such studies is that SGLT-1-mediated glucose transport can be studied uncomplicated by interference from GLUT-2 transporters or cytoplasmic glucose metabolism.

Isolated hepatocyte suspensions provide a good model for studying insulin-like or glucagon-antagonistic activity. One enzyme that may be studied is hepatic glycogen phosphorylase (HGPa), which causes the degradation of glycogen to glucose-1-phosphate. However, in vitro, the activity of the enzyme is studied using the reverse reaction. Insulin has been shown to reduce the activity of this enzyme in the absence of glucagon as well as counteracting the glucagon stimulation of HGPa.

MATERIALS AND METHODS

Materials

All chemicals were obtained from Sigma Chemical Company (Poole, Dorset, UK). Commercial fenugreek seed was purchased from an Indian supermarket in North London. A voucher specimen (number Tr 91 Kg) has been deposited in the Pharmacognosy Research Laboratories, Pharmacy Department, Kings College London.

Extraction and Phytochemical Work

Preparation of Extracts

Fenugreek seed (1 kg) was ground in a Maig grinder to pass through a 0.8 mm mesh sieve and continuously extracted (Soxhlet apparatus) with light petroleum (40/60°C) for 16 hours. The extract was dried by rotary evaporation under vacuum to yield an oil fraction (A; 45 g). The defatted fenugreek seed powder (895 g) was dried at room temperature and continuously extracted with absolute ethanol for 24 hours. Drying as before yielded the crude ethanolic extract (B; 65 g). A portion of B was re-dissolved in water and further extracted by n-butanol (500 ml) in a separating funnel. A saponin extract (C; 16.9 g) was obtained by evaparing the n-butanol layer, leaving the water layer containing saponin-free extract (D; 13.7 g on freeze drying). An aglycone extract (E; 6.75 g) was obtained by hydrolysis of the saponin extract (C; 9.2 g) by refluxing it with H2SO4 (10%, 20 ml) for 30 minutes and then extracting it with equal volume of chloroform, which was later dried under vacuum.

Gum fibre was extracted according to a previously reported method. Defatted seed powder (1 g) was extracted with acetic acid (5% aqueous, 100 ml) by continual stirring at room temperature for 30 minutes. The mixture was centrifuged (30 minutes; 20,000 rpm) and the supernatant was recovered. The above acetic acid extraction of the sediment and centrifugation was repeated 3-times. Supernatants were pooled together and gum fibre precipitated by addition of absolute ethanol to 50% v/v with continuous stirring. The suspension was centrifuged (10,000 rpm; 15 minutes). The supernatant was decanted and the precipitate washed with absolute ethanol and acetone. The hair-like precipitate was collected by filtration (F; 90 mg).

Preparation of Fractions for Bioassay

Due to their poor water-solubility, the fractions were solubilized in 0.3% v/v Tween-80 for testing. The latter solution was used as the control in these experiments. The fibre fraction produced a thick gel on dissolving in 0.3% Tween 80 and was only tested at a concentration of 0.33 mg/ml.

Flash Chromatography

The aglycone fraction (E; 1.09 g) was subjected to silica gel flash chromatography (Kieselgel 60, 40–63 μm; 40 g), eluting successively with 200 ml volumes of petroleum ether, petroleum ether-chloroform (1:1), chloroform, chloroform-methanol (19:1, 9:1, 5:1, 4:1, and 1:1) and
methanol. Eluate was collected as 100ml fractions, which were concentrated and compared with parent extract (E) using silica-gel thin-layer chromatography (TLC; solvent: chloroform:methanol, 19:1, plate dried and transferred to a second tank containing chloroform:methanol:water, 65:35:10). TLC zones were detected using anisaldehyde spray reagent (anisaldehyde:methanol:sulphuric acid:acetic acid, 0.5:85:10:5) followed by heating at 105°C. Fractions of similar chemical constituents were pooled together. The major fraction (G; 0.83g) eluted with chloroform.

Glucose Content of Extracts
The presence of sugars (glucose, galactose and fructose) in the extracts was determined qualitatively by TLC and quantitatively by high performance liquid chromatography (HPLC).

TLC system: Silica gel G, developed with ethylacetate/acetic acid/methanol/H2O (60:15:15:10); detection with anisaldehyde spray reagent as described above.

HPLC system: Apex NH2 silica column (5µ; 15cm), acetonitrile/H2O (80:20) mobile phase; refractive index detection; internal standard maltose.

Intestinal Glucose Uptake Experiments
Preparation of Rabbit Intestine
The small intestine of a New-Zealand White rabbit (killed by administration of sodium pentobarbitone) was dissected from the pyloric sphincter to the ileo-caecal junction and put into ice-cold KCl solution (154mM). The remaining mesentery and fat were thoroughly removed, the intestine transferred to fresh ice-cold KCl solution and the contents gently squeezed out. The small intestine was cut longitudinally and washed thoroughly in KCl solution. It was then blotted dry with paper tissue, snap frozen in a plastic bag in liquid nitrogen, and stored at −70°C.

Preparation of BBMV
BBMV were prepared from the tips of the microvilli of rabbit cleaned small intestine using the divalent-cation precipitation method as modified by Kessler et al. (1978).[21] Frozen small intestine was thawed in Buffer 1 (200ml; D-mannitol 10mM, HEPES 2mM, Tris to pH 7.4). Epithelium was separated from the underlying mucosa by mechanical vibration on a VIBRO mixer at maximum speed (1min), cooling in ice (1min), followed by further vibration (30s). The solution was filtered under vacuum through a Buchner funnel, without filter paper, to remove muscle debris. The filtrate was made up to volume (300ml) with Buffer 1 and solid MgCl2 (0.61g) added. After stirring (0°C, 20min), the suspension was centrifuged (3015g, 4°C, 15min). The resultant supernatant was centrifuged (34858g, 4°C, 30min) and the supernatant discarded. The pellet was resuspended in Buffer 2 (8ml; D-mannitol 100mM, MgSO4 0.1mM, HEPES 2mM, Tris to pH 7.4). The resuspended pellet was centrifuged (34858g, 4°C, 40min) and the supernatant discarded. The resultant washed pellet was resuspended in 3 times the pelletted volume in Buffer 3 (mannitol 300mM, MgSO4 0.1mM, HEPES 10mM, Tris to pH 7.4). The suspension was passed 5 times through a 25 gauge needle, aliquoted in 0.26 ml volumes and snap frozen in liquid nitrogen. Prior to use, each aliquot (0.26ml) of BBMV was diluted with Buffer 3 (0.44ml). This final suspension will be referred to as the BBMV suspension.

BBMV Protein Content
Protein content of the BBMV suspension (diluted 1:10, 1:50 and 1:100 in water) was assayed against bovine serum albumin using Coomassie blue as per the Bradford method.[29]

Glucose Uptake Studies
Glucose uptake was determined by the rapidfiltration method of Hopfer et al.[30] BBMV
IN VITRO ANTI-DIABETIC PROPERTIES OF FENUGREEK

A suspension (20 μl) was incubated at 25°C with radio-labelled D-glucose in buffer (20 μl; glucose 0.2 mM, NaSCN 200 mM, D-mannitol 200 mM, HEPES 20 mM, Tris to pH 7.4, containing 3H-D-glucose 0.3 MBq per ml) and either test (extract) dissolved in 0.3% Tween 80, 0.3% Tween 80 solution, or water (20 μl). Reaction was initiated by addition of BBMV suspension, and terminated at the required time by addition of ice-cold stopwash buffer (1 ml; NaCl 200 mM, phlorizin 250 μM, 10 mM HEPES, Tris to pH 7.4). The solution was filtered under vacuum through a prewetted cellulose acetate/nitrate filter (0.45 μm; Millipore). The sample tube was rinsed with stopwash buffer (2 × 1 ml) which was also passed through the filter. The filter paper was transferred to a scintillation vial containing Ready-Protein scintillant (Beckman, Ireland). Radioactivity was counted for 300s in a scintillation counter (LKB Wallac 1209 Rackbeta). The time course of glucose uptake was determined by terminating incubations containing BBMV, glucose buffer and water at short intervals over a one minute period (Fig. 1). Some incubations were continued to 5 minutes or 1 hour to ensure that equilibrium was obtained (Fig. 1). Performance of vesicles was routinely checked by ensuring that a satisfactory peak to equilibrium ratio was obtained.

For calculation of % inhibition, data from incubations terminated at 20 seconds (corresponding to peak glucose uptake) were used. Data were statistically analysed by one way ANOVA and t-test. Glucose uptake was expressed (Tab. I) as pmol glucose/mg protein ± SEM of three different intestinal preparations (n = 6 for each preparation).

### TABLE I  Glucose uptake into intestinal BBMVs in the presence of extracts of Fenugreek seeds

<table>
<thead>
<tr>
<th>Test substance</th>
<th>Glucose uptake with test substance at:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3.3 mg/ml (a)</td>
</tr>
<tr>
<td>A - Oil fraction</td>
<td>442.5 ± 17.6 (88%)</td>
</tr>
<tr>
<td>B - Crude extract</td>
<td>362.8 ± 6.9* (72%)</td>
</tr>
<tr>
<td>C - Saponin-free extract</td>
<td>183.2 ± 8.9* (37%)</td>
</tr>
<tr>
<td>D - Saponin extract</td>
<td>116.5 ± 7.1* (23%)</td>
</tr>
<tr>
<td>E - Aglycone extract</td>
<td>94.1 ± 1.4* (19%)</td>
</tr>
<tr>
<td>F - Fibre</td>
<td>ND</td>
</tr>
<tr>
<td>G - Main aglycone fraction</td>
<td>270.9 ± 7.8* (54%)</td>
</tr>
<tr>
<td>Diosgenin</td>
<td>274.8 ± 10.1* (55%)</td>
</tr>
<tr>
<td>Trigonelline</td>
<td>226.8 ± 10.5* (45%)</td>
</tr>
</tbody>
</table>

Data given as mean ± SEM of three separate BBMV preparations (n = 6 for each preparation). Control values 574.7 ± 15.6 and 501.7 ± 14.9 pmol glucose/mg protein for water and 0.3% Tween 80 respectively. (a) Expressed as pmol glucose/mg protein; (b) expressed as a % of the 0.3% Tween 80 control; ND - not determined. * = p < 0.001, with respect to Tween-80 (control); § - not significantly different from water control.
Isolated Hepatocyte Suspension Experiments

Preparation of Hepatocyte Suspensions

Rat isolated hepatocyte suspensions were prepared by a collagenase perfusion method and adjusted to $3 \times 10^6$ cells per ml with Krebs' medium. Aliquots were gassed with O$_2$/CO$_2$ (19:1) for 15 seconds.

Test Incubations

Following a pre-incubation period of 30 minutes, hepatocyte suspension (450μl) was transferred to 1 ml microcentrifuge tubes containing either 50μl of test sample, 50μl vehicle control, or 25μl of glucagon (10μM) and 25μl of either test sample or vehicle control. Once mixed the sample tubes were incubated at 37°C on a dry heating block for 4 minutes. The incubation was stopped by rapidly freezing the tubes and storing them at −80°C.

HGPα Assay

Crude HGPα was released from hepatocytes by adding an equal volume (500μl) of ice-cold MOPS buffer (100mM MOPS, 200mM NaF, 30mM NaEDTA, 10mM dithiothreitil) to the frozen sample which was then left to thaw on ice. Hepatocytes were sonicated for 60 seconds and the lysate vortexed and centrifuged (10 min; 2500g; 4°C).

To measure HGPα activity, 50μl aliquots of the supernatant were transferred to 1 ml microcentrifuge tubes containing 50μl of radioactive assay mixture (2% glycogen, 1mM caffeine, 100mM glucose-1-phosphate, 50nM 14C-glucose-1-phosphate (specific activity 50GBq/mmol). This mixture was vortexed and incubated in a water bath for 20 minutes at 37°C and the reaction stopped by placing the sample tubes on an ice-bath. Aliquots of reaction mixture (30μl) were spotted onto 1 cm$^2$ filter paper pieces, washed 3 times with 66% (v/v) ethanol in water, followed by a wash in acetone for 1 minute and allowed to dry. The filter paper pieces were transferred into scintillation vials, 5mL of scintillant fluid (Ecoscintillant A) added and counted for radioactivity. The results were statistically analysed by one way ANOVA and t-test. HGPα activity (Tab. II) is expressed as nmol of 14C-glucose-1-phosphate incorporated into glycogen per mg of protein per minute ± SEM of three different hepatocyte preparations (n = 3 for each preparation).

<table>
<thead>
<tr>
<th>Test substance $^a$</th>
<th>+Glucagon ($a$)</th>
<th>−Glucagon ($b$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tween-80</td>
<td>25.8 ± 1.1 (100%)</td>
<td>22.2 ± 0.5 (100%)</td>
</tr>
<tr>
<td>A - Oil fraction</td>
<td>20.5 ± 1.6 (80%)</td>
<td>26.9 ± 2.3 (100%)</td>
</tr>
<tr>
<td>B - Crude extract</td>
<td>21.7 ± 2.1 (84%)</td>
<td>22.0 ± 1.1 (99%)</td>
</tr>
<tr>
<td>C - Saponin-free extract</td>
<td>20.6 ± 0.2* (80%)</td>
<td>24.9 ± 1.0 (112%)</td>
</tr>
<tr>
<td>D - Saponin extract</td>
<td>22.7 ± 3.6 (88%)</td>
<td>23.5 ± 1.0 (106%)</td>
</tr>
<tr>
<td>E - Aglycone extract</td>
<td>21.6 ± 0.7* (84%)</td>
<td>25.2 ± 1.9 (113%)</td>
</tr>
<tr>
<td>Diosgenin</td>
<td>20.4 ± 0.3* (79%)</td>
<td>22.5 ± 1.9 (101%)</td>
</tr>
<tr>
<td>Trigonelline</td>
<td>23.1 ± 1.2 (89%)</td>
<td>23.1 ± 0.8 (104%)</td>
</tr>
</tbody>
</table>

Data given as mean ± SEM of three separate hepatocyte preparations (n = 3 for each preparation). $^a$Fractions were tested at 3.3mg/ml in experiments without glucagon and 1.65mg/ml with glucagon. (a) Results expressed as nmol glucose/mg protein/min, (b) results expressed as a % of the Tween-80 control. * = p < 0.05, with respect to Tween-80 (control).
RESULTS AND DISCUSSION

Figure 1 shows typical profiles of glucose uptake into BBMV obtained in control (0.3% Tween 80) incubations and with 2 fenugreek fractions. All extracts as well as diosgenin and trigonelline were found to decrease the area under the glucose uptake profile without altering the equilibrium glucose concentration at 3600s, indicating that the integrity of the BBMV was maintained. Tween 80 (0.3% v/v), was also found not to alter the integrity of the vesicles compared to water as shown by a non-significant difference in peak glucose uptake (Tab. I) and no difference in the equilibrium value at 3600s (data not shown). Furthermore, we have found\(^\text{[321]}\) that the addition of phloridzin (an SGLT-1 inhibitor\(^\text{[261]}\)) decreases peak glucose uptake in a dose-dependent manner (IC\(_{50}\) of 250\(\mu\)M\(^\text{[321]}\), thus validating the use of this model for the study of glucose uptake via SGLT-1. Although GLUT-2 transporters are primarily located in the basolateral membrane of the enterocytes, their glucose-induced recruitment to the brush border membrane has clearly been demonstrated in perfused rat jejunum.\(^\text{[33]}\) Indeed lower levels of GLUT-2 could be detected in rat BBMV even in the absence of glucose in the perfusate.\(^\text{[33]}\) Nevertheless, it seems unlikely that GLUT-2 mediated transport occurs to any significant extent in the BBMV model reported in the present study since the uptake of labelled glucose into the vesicles was unaffected by the presence of up to 8mM fructose (data not presented), whereas fructose and glucose are known to exert mutual inhibition of uptake via GLUT-2 transporters.\(^\text{[34]}\)

With the exception of the petroleum ether extract (oil fraction, A) all the extracts significantly reduced (\(p < 0.0001\)) glucose uptake at the higher or both concentrations (Tab. I). Both layers derived from partitioning of the crude ethanol extract (B) inhibited uptake, indicating that both saponin (D) and non-saponin (C) constituents may be involved. There was no loss of activity on hydrolysing the saponins, indeed the greatest inhibition of glucose uptake was seen in the hydrolysed extract (E), believed to contain sapogenins (aglycones). On further fractionation of (E) by flash chromatography the main fraction G from this extract inhibited glucose uptake by 46%; whereas the other subfractions showed weaker inhibition (data not shown). The observed inhibition of glucose uptake in the aglycone fraction and its subfraction did not appear to be due to diosgenin or trigonelline, since no diosgenin or trigonelline could be detected in these fractions by TLH. Furthermore, diosgenin and trigonelline at 3.3mg/ml inhibited glucose uptake by only 45% and 55% as compared to the 81% inhibition by 3.3mg/ml of Extract (E). Of these two compounds diosgenin (8mM) was more potent than trigonelline (19.2mM). This suggests that diosgenin and trigonelline are not solely responsible for the effects seen with the crude extract. Further, in comparison to phloridzin (IC\(_{50}\) 0.3mM)\(^\text{[321]}\) these two compounds exhibited very weak inhibition of this transporter.

Analysis of the sugar content of the extracts showed the presence of small quantities of glucose (0.016mM at 3.3mg/ml) and a negligible amount of fructose in the crude extract (B), considerably less in other extracts (<0.01mM) and none in the hydrolysed extract (E). This confirms that the inhibition of radiolabelled glucose uptake into BBMV by the fractions was not due to competition by unlabelled glucose in the fractions at the concentrations used.

The effect of the fenugreek extracts on the activity of HPGa activity is shown in Table II. None of the extracts (at 3.3mg/ml) inhibited the enzyme in the absence of glucagon, suggesting that an insulinomimetic effect was not present. By contrast, in the presence of glucagon, fenugreek extracts (at 1.65mg/ml) inhibited the enhanced HPGa activity by between 11–20% as compared to the control. However, this was only statistically significant (\(p < 0.05\)) with the saponin-free C (18.9%) and the sapogenin E (15.1%) fractions and
diosgenin. The observed inhibition of HGPa activity in the aglycone fraction is unlikely to be due to diosgenin or trigonelline, since these compounds could not be detected in this fraction by silica-gel TLC. Nevertheless, diosgenin, but not trigonelline, affected HGPa activity. At 8mM diosgenin significantly inhibited the enzyme activity by 20%. These results suggest that some components of fenugreek may be able to counteract the effects of the hormone glucagon. Fenugreek methanol and water extracts have also been shown to reduce HGPa activity induced by adrenaline in hepatocytes.\[35\]

In conclusion, these results show that fenugreek seeds contain substances capable of inhibiting the SGLT-1 mediated absorption of glucose across the brush border membrane of intestinal vesicles. The most active substance(s) with regard to inhibition of SGLT-1 seem to be non-lipid in nature, with the aglycone extract showing greatest activity. The results may well be relevant to the in vivo situation in that concentrations of about 3mg/mL or less of fenugreek extract are attainable in the intestine, and the moieties reaching the small intestine are more likely to be aglycones than saponin glycosides (which would be hydrolysed by stomach acids). The active compound(s) are unlikely to be, but may be related to, diosgenin or trigonelline, two compounds previously associated with the medicinal properties of fenugreek. Further work to characterise the mechanism (competitive or non-competitive) by which SGLT-1 is inhibited by these extracts could only be undertaken once pure compounds are isolated from the active fractions, as the use of mixtures may complicate the results of such experiments.

Fenugreek seeds also seem to contain substances capable of affecting hepatic glycogen metabolism by inhibiting glucagon-induced HGPa activity in isolated liver hepatocytes. This activity was associated with the aglycone and saponin-free extracts. Although only a weak effect was observed at a concentration of 1.65mg/mL, it is possible that the crude extracts used contain low concentrations of the actual active species, which if isolated would be effective at lower, and therefore more physiologically relevant concentrations.

These potential intestinal and hepatic effects of constituents of fenugreek seeds may explain the anti-diabetic effects of fenugreek observed by other researchers in various human and animal models.[4]

Acknowledgement

The authors thank the British Council (Yemen) for financing these investigations by the award of a grant to MAH.

References

IN VITRO ANTI-DIABETIC PROPERTIES OF FENUGREEK


Submit your manuscripts at http://www.hindawi.com